Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robin Michelet

Showing results (61-70 of 74) with videos related to

Pageof 8
Sort By:
Cells|April 3, 2021
Constitutive Cell Proliferation Regulating Inhibitor of Protein Phosphatase 2A (CIP2A) Mediates Drug Resistance to Erlotinib in an EGFR Activating Mutated NSCLC Cell LineHisham Saafan, Ahmad Alahdab, Robin Michelet, et al.
Antibiotics (Basel, Switzerland)|April 30, 2021
Evaluation of the MeroRisk Calculator, A User-Friendly Tool to Predict the Risk of Meropenem Target Non-Attainment in Critically Ill PatientsUwe Liebchen, Marian Klose, Michael Paal, et al.
Pharmaceuticals (Basel, Switzerland)|March 29, 2023
Model-Informed Target Morning 17α-Hydroxyprogesterone Concentrations in Dried Blood Spots for Pediatric Congenital Adrenal Hyperplasia PatientsViktoria Stachanow, Uta Neumann, Oliver Blankenstein, et al.
Infection|April 25, 2025
Model-informed identification of optimised dosing strategies for meropenem in critically ill patients receiving SLEDD: an observational studyFranz Weber, Christina Scharf, Linda B S Aulin, et al.
CPT: Pharmacometrics & Systems Pharmacology|December 10, 2024
A minimal physiologically-based pharmacokinetic modeling platform to predict intratumor exposure and receptor occupancy of an anti-LAG-3 monoclonal antibodyRobin Michelet, Klas Petersson, Marc C Huisman, et al.
CPT: Pharmacometrics & Systems Pharmacology|March 24, 2023
Barriers to global pharmacometrics: educational challenges and opportunities across the globeRobin Michelet, Linda B S Aulin, Jens M Borghardt, et al.
Pharmaceutics|April 30, 2021
The Use of Translational Modelling and Simulation to Develop Immunomodulatory Therapy as an Adjunct to Antibiotic Treatment in the Context of PneumoniaRobin Michelet, Moreno Ursino, Sandrine Boulet, et al.
Antibiotics (Basel, Switzerland)|June 24, 2022
Evaluation of a Meropenem and Piperacillin Monitoring Program in Intensive Care Unit Patients Calls for the Regular Assessment of Empirical Targets and Easy-to-Use Dosing Decision ToolsFerdinand Anton Weinelt, Miriam Songa Stegemann, Anja Theloe, et al.
BMJ Open|January 4, 2022
Plasma concentration guided dosing of drugs used for the treatment of childhood leukaemias: protocol for a systematic reviewMadelé van Dyk, Chelsea Boylan, Robin Michelet, et al.
Cancer Chemotherapy and Pharmacology|June 15, 2024
Population pharmacokinetics of TLD-1, a novel liposomal doxorubicin, in a phase I trialAnna M Mc Laughlin, Dagmar Hess, Robin Michelet, et al.
Pageof 8

Showing results (61-70 of 74) with videos related to

Sort By:
Pageof 8
Cells|April 3, 2021
Constitutive Cell Proliferation Regulating Inhibitor of Protein Phosphatase 2A (CIP2A) Mediates Drug Resistance to Erlotinib in an EGFR Activating Mutated NSCLC Cell LineHisham Saafan, Ahmad Alahdab, Robin Michelet, et al.
Antibiotics (Basel, Switzerland)|April 30, 2021
Evaluation of the MeroRisk Calculator, A User-Friendly Tool to Predict the Risk of Meropenem Target Non-Attainment in Critically Ill PatientsUwe Liebchen, Marian Klose, Michael Paal, et al.
Pharmaceuticals (Basel, Switzerland)|March 29, 2023
Model-Informed Target Morning 17α-Hydroxyprogesterone Concentrations in Dried Blood Spots for Pediatric Congenital Adrenal Hyperplasia PatientsViktoria Stachanow, Uta Neumann, Oliver Blankenstein, et al.
Infection|April 25, 2025
Model-informed identification of optimised dosing strategies for meropenem in critically ill patients receiving SLEDD: an observational studyFranz Weber, Christina Scharf, Linda B S Aulin, et al.
CPT: Pharmacometrics & Systems Pharmacology|December 10, 2024
A minimal physiologically-based pharmacokinetic modeling platform to predict intratumor exposure and receptor occupancy of an anti-LAG-3 monoclonal antibodyRobin Michelet, Klas Petersson, Marc C Huisman, et al.
CPT: Pharmacometrics & Systems Pharmacology|March 24, 2023
Barriers to global pharmacometrics: educational challenges and opportunities across the globeRobin Michelet, Linda B S Aulin, Jens M Borghardt, et al.
Pharmaceutics|April 30, 2021
The Use of Translational Modelling and Simulation to Develop Immunomodulatory Therapy as an Adjunct to Antibiotic Treatment in the Context of PneumoniaRobin Michelet, Moreno Ursino, Sandrine Boulet, et al.
Antibiotics (Basel, Switzerland)|June 24, 2022
Evaluation of a Meropenem and Piperacillin Monitoring Program in Intensive Care Unit Patients Calls for the Regular Assessment of Empirical Targets and Easy-to-Use Dosing Decision ToolsFerdinand Anton Weinelt, Miriam Songa Stegemann, Anja Theloe, et al.
BMJ Open|January 4, 2022
Plasma concentration guided dosing of drugs used for the treatment of childhood leukaemias: protocol for a systematic reviewMadelé van Dyk, Chelsea Boylan, Robin Michelet, et al.
Cancer Chemotherapy and Pharmacology|June 15, 2024
Population pharmacokinetics of TLD-1, a novel liposomal doxorubicin, in a phase I trialAnna M Mc Laughlin, Dagmar Hess, Robin Michelet, et al.
Pageof 8